GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced that its Board of Directors has approved a 1-for-24 reverse stock split of its issued and outstanding common stock. The move is intended to regain compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The reverse stock split was approved by stockholders at a meeting held on October 27, 2026.
The reverse stock split will become effective at 12:01 a.m. Eastern Time on November 11, 2026, and the common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Stock Exchange at the market open that day. Following the split, the stock will continue to trade under the symbol “GOVX,” with a new CUSIP number 373678 804. On the effective date, every 24 issued and outstanding shares will be automatically converted into one share, with no change in the $0.001 par value per share. As a result, the total number of issued and outstanding shares will decrease from 12,209,871 to approximately 508,745.
According to the company, each stockholder’s percentage ownership interest and proportional voting power will remain unchanged immediately after the split, aside from minor adjustments resulting from the rounding of fractional shares to the nearest whole number. The rights and privileges of common stock holders will be substantially unaffected.
The reverse split matters because a sub-$1.00 share price can jeopardize a company’s Nasdaq listing, which in turn affects liquidity, institutional ownership, and access to capital. For GeoVax, maintaining its Nasdaq listing is particularly important as it advances its clinical programs. The company’s priority program is GEO-MVA, a Modified Vaccinia Ankara–based vaccine targeting mpox and smallpox. It is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in late 2026 to address global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. The company also maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities.
Investors should note that while a reverse split can restore bid-price compliance, it does not change the underlying fundamentals of the business. The company’s forward-looking statements acknowledge risks related to clinical trial results, regulatory approvals, manufacturing, competition, and capital raising. GeoVax’s ability to execute on its pipeline and secure necessary funding will ultimately determine the long-term impact of this corporate action. More information about the company is available at www.geovax.com. The announcement was issued via NEWMEDIAWIRE.
